Takeda (TAK.US) partners with Keros Therapeutics to develop innovative therapies for blood diseases

Market IntelWednesday, Dec 4, 2024 2:40 am ET

1min read

Keros Therapeutics today (December 4) announced a global exclusive license agreement with Takeda (TAK.US) to advance the development of elritercept. Elritercept is currently in two Phase 2 clinical trials, one in patients with low-risk or intermediate-risk myelodysplastic syndrome (MDS) and another in patients with myelofibrosis (MF). In addition, the Phase 3 clinical trial RENEW will soon start patient enrollment to evaluate the efficacy of elritercept in adult patients with low-risk or intermediate-risk MDS who are dependent on transfusions. Under the terms of the agreement, Takeda will gain exclusive rights to further develop, manufacture, and commercialize elritercept worldwide (excluding Mainland China, Hong Kong, and Macau). Takeda will take over all development, manufacturing, and commercialization of elritercept as of the effective date of the agreement. Keros will receive a $200 million upfront payment and is eligible to receive over $1.1 billion in development, regulatory, and commercial milestone payments.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.